Related Experiment Video
Updated: Nov 12, 2025

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
Discrete binding patterns of two heparin-reactive proteins, basic fibroblast growth factor and peptide p5R, in
Emily B Martin1, Robert Donnell2, Tina Richey1
1Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA.
Abstract:
Peptide p5R is a synthetic, polybasic, heparin-binding peptide that preferentially reacts with amyloid deposits in vivo and in tissue sections. Basic fibroblast growth factor (bFGF1) similarly interacts with heparin-like molecules, notably heparan sulfate proteoglycans (HSPG), in the extracellular matrix and on cell surfaces. The aim of this study was to compare the biodistribution of p5R and bFGF in healthy mice as well as those with systemic inflammation-associated amyloidosis (AA), which contains HSPG, by using SPECT/CT imaging, tissue biodistribution measurements and micro-autoradiography. Although both proteins are known to bind heparan sulfate, their biodistribution was remarkably different in the healthy and diseased animals. Imaging revealed uptake of both radiolabeled proteins in the liver, spleen, and kidneys of mice with amyloidosis; however, 125I-bFGF, but not 125I-p5R, was observed in normal tissue at sites of HSPG expression, including the hepatic and splenic sinusoids and renal glomerulae. Microautoradiography demonstrated that while p5R bound exclusively to amyloid deposits in the spleen and liver of AA mice, bFGF had a broader binding pattern. Consequently, even though bFGF and p5R both interact with heparan sulfate moieties, p5R binding was restricted to HSPG in amyloid deposits and did not bind HSPG in healthy tissues, whereas bFGF preferentially reacted with HSPG in normal tissue. The data suggest that peptide p5R selectively binds HSPG in amyloid and that the HSPG in healthy tissue, recognized by bFGF, is not targeted by the peptide.
Insights
Peptide p5R selectively targets amyloid deposits by binding to heparan sulfate proteoglycans (HSPG) within them. Unlike basic fibroblast growth factor (bFGF), p5R avoids binding HSPG in healthy tissues, suggesting targeted amyloid detection.
Area of Science:
- Biomedical research
- Molecular imaging
- Peptide therapeutics
Background:
- Peptide p5R and basic fibroblast growth factor (bFGF) bind heparin-like molecules.
- Heparan sulfate proteoglycans (HSPG) are involved in extracellular matrix and cell surface interactions.
- Amyloidosis involves the accumulation of amyloid deposits, which can contain HSPG.
Purpose of the Study:
- To compare the biodistribution of peptide p5R and bFGF in healthy and amyloidotic mice.
- To investigate the selective binding of p5R to amyloid deposits versus bFGF.
Main Methods:
- SPECT/CT imaging to track radiolabeled p5R and bFGF.
- Tissue biodistribution measurements.
- Micro-autoradiography for detailed binding analysis.
Main Results:
- Both p5R and bFGF accumulated in the liver, spleen, and kidneys of amyloidotic mice.
- 125I-bFGF, but not 125I-p5R, bound to HSPG in healthy tissues.
- p5R exclusively bound to HSPG in amyloid deposits, while bFGF showed broader binding.
Conclusions:
- Peptide p5R selectively binds to HSPG within amyloid deposits.
- p5R demonstrates targeted binding to amyloid, unlike bFGF which binds to HSPG in both healthy and diseased tissues.
- This selectivity suggests p5R's potential for targeted amyloid imaging or therapy.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils

